Nasalcrom
This article was originally published in The Tan Sheet
Executive Summary
FDA requests studies in the pediatric population for Pharmacia & Upjohn's cromolyn sodium nasal spray. If P&U submits studies that are considered sufficient by the agency, Waxman/Hatch marketing exclusivity for the product would be extended by six months from its current expiration on Jan. 3, 2000. The product, which is indicated for both prevention and treatment of allergy symptoms, was approved in January 1997 ("The Tan Sheet" Jan. 13, 1997, p. 1). The original sponsor of the drug was McNeil Consumer Healthcare; P&U acquired the brand in a June 1997 trade with McNeil ("The Tan Sheet" June 9, 1997, p. 2)
You may also be interested in...
Supplement GMP Warning Letters Make Modest Debut In 2010
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC
In Brief
Combe sells most of its OTC brands
People In Brief
Perrigo promotes in pricing, planning